|
The
following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they
would be anti-dilutive:
Schedule of Potentially Dilutive Securities
| |
|
2023 |
|
|
2022 |
|
| |
|
September
30, |
|
| |
|
2023 |
|
|
2022 |
|
| Common
stock warrants August 2021 |
|
|
128,500 |
|
|
|
128,500 |
|
| Underwriter
warrants August 2021 |
|
|
2,287 |
|
|
|
2,287 |
|
| Private
warrants |
|
|
— |
|
|
|
332 |
|
| Chanticleer
warrants |
|
|
57 |
|
|
|
57 |
|
| Series
C warrants |
|
|
36,778 |
|
|
|
36,778 |
|
| Series
3 warrants |
|
|
12,548 |
|
|
|
12,548 |
|
| Unvested
restricted stock units and awards |
|
|
2,326 |
|
|
|
2,162 |
|
| Common
stock warrants February 2023 |
|
|
271,883 |
|
|
|
— |
|
| Underwriter
warrants February 2023 |
|
|
44,190 |
|
|
|
— |
|
| Common
stock private placement warrants June 2023 |
|
|
227,272 |
|
|
|
— |
|
| Placement
agent warrants June 2023 |
|
|
6,818 |
|
|
|
— |
|
| Total
anti-dilutive weighted average shares |
|
|
732,659 |
|
|
|
182,664 |
|
|